Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
|Articles|April 4, 2017
Robotic Vial Filling and Capping Machine under Isolator
Author(s)Steriline S.r.l.
Steriline is an expanding European manufacturer founded in the Lake Como area in 1989, highly specialized in the production of complete lines for the aseptic processing of injectable products, supplying pharmaceutical companies worldwide.
Advertisement
STERILINE is proud to introduce its new Robotic Vial Filling and Capping Machine for injectable products fully under in-house engineered and manufactured Isolators integrated with the latest VHP technology.
The machine was designed and manufactured jointly with the German pharmaceutical company AqVida.
The key features are:
- 3 VHP resistant robotic arms from STÄUBLI Robotics based in Switzerland
- Peristaltic pumps actuated by servomotors, that allow precise filling and easy adjustment of the pumps by means of the HMI
- “No loss / zero waste philosophy” resulting in all missing stoppers / caps being collected and re-applied during the process
- 100% in-line Check Weighing System integrated in the filling station
- The vials range that can be treated goes from 2ml to 100ml, without changing any format parts, with an estimated output of approx. 6.000 vials/h satisfying at the best the customer requirements in terms of flexibility on the one hand and efficiency on the other
The line is installed in the new AqVida plant in Dassow.
Contact details:
Company name: Steriline Srl
Website: www.steriline.it
E-mail:
Advertisement
Related to this article
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Advertisement
Advertisement